Cov Txiaj Ntsig Zoo rau CD7 CAR-T Kev Kho Mob hauv Kev Kho Mob Rov Qab Los / Refractory Peripheral T-Cell Lymphoma ntawm ASH 2024

Nyob rau ntawm Lub Rooj Sib Tham Txhua Xyoo 66th ntawm American Society of Hematology (ASH) 2024, uas tau muaj txij hnub tim 7 txog 10 Lub Kaum Ob Hlis hauv San Diego, Xibfwb Lu Peihua ntawm Tsev Kho Mob Lu Daopei tau nthuav tawm qhov kev sim tshuaj theem I ntawm CD7-targeted Chimeric Antigen Receptor T-cell (CAR-T) kev kho mob rau kev kho mob ntawm cov kab mob rov qab los / refractory peripheral. T-Cell Lymphoma (R/R PTCL). Qhov no yog ib qho kev tshawb pom tseem ceeb hauv kev kho mob T-cell malignancies, qhov twg cov kev xaiv kho mob muaj tsawg thiab feem ntau tsis zoo.

R/R PTCL paub txog nws qhov kev kwv yees tsis zoo, tshwj xeeb tshaj yog rau cov neeg mob uas tau dhau ntau txoj kev kho mob, suav nrog allogeneic hematopoietic stem cell transplantation (allo-HSCT). Txawm li cas los xij, CD7 CAR-T therapy, tshwj xeeb tshaj yog NS7CAR-T cell therapy tsim los ntawm Prof. Lu pab pawg, tau pom tias muaj txiaj ntsig zoo hauv kev kho cov neeg mob uas muaj CD7-positive R/R PTCL. Hauv qhov kev sim no, tag nrho tsib tus neeg mob, hnub nyoog 39 txog 60, nrog rau theem siab ntawm R/R PTCL tau sau npe ntawm lub Plaub Hlis 2021 thiab Kaum Ib Hlis 2023. Cov neeg mob no tau dhau qhov nruab nrab ntawm rau txoj kev kho mob yav dhau los, suav nrog ib rooj plaub nrog keeb kwm ntawm autologous stem cell transplantation.

Cov txiaj ntsig tau zoo heev: nyob rau hauv lub sijhawm saib xyuas nruab nrab ntawm 234 hnub, 60% ntawm cov neeg mob tau txais kev zam txim tag nrho (CR), thiab ib tus neeg mob tau txais kev zam txim ib nrab (PR). Qhov tseem ceeb, kev kho mob tau qhia txog qib siab ntawm CAR-T cell proliferation thiab nyob ntev hauv cov neeg mob, nrog rau qib siab tshaj plaws ntawm CAR-T cell ncav cuag 93.5% kev ua haujlwm. Qhov tseem ceeb, tsis muaj cov teebmeem tsis zoo xws li neurotoxicity, thiab cytokine release syndrome (CRS) tsis hnyav, tsuas yog ib tus neeg mob uas muaj qib II CRS. Cov ntaub ntawv kev nyab xeeb tau tswj tau, tsis muaj kev lom hnyav pom.

Kev tshawb fawb ntawm Xibfwb Lu qhia txog lub peev xwm ntawm CD7 CAR-T kev kho mob ua ib qho kev hloov pauv hauv kev kho mob T-cell malignancies, tshwj xeeb tshaj yog rau cov neeg mob uas muaj ob peb lossis tsis muaj kev xaiv kho mob ntxiv lawm. Ntxiv nrog rau cov txiaj ntsig zoo hauv PTCL, Xibfwb Lu pab neeg tau ua tiav qhov ua tau zoo hauv kev kho mob T-cell acute lymphoblastic leukemia (T-ALL) thiab T-cell lymphoblastic lymphoma (T-LBL), nrog rau yuav luag 95% kev zam txim tiav hauv ib pawg neeg ntawm 60 tus neeg mob. Muab cov txiaj ntsig no, pab neeg tam sim no tab tom nthuav lawv txoj kev tshawb fawb mus rau lwm yam mob hematological xws li mob ntshav siab myeloid leukemia (AML), nrog rau cov ntaub ntawv thaum ntxov qhia txog 70% kev zam txim tiav hauv cov neeg mob CD7-positive AML.

Txawm hais tias muaj cov txiaj ntsig zoo no los xij, Xibfwb Lu hais txog qhov tseem ceeb ntawm kev sib koom ua ke CD7 CAR-T kev kho mob nrog allo-HSCT los txhim kho cov txiaj ntsig mus sij hawm ntev. Qhov sib txawv ntawm T-cell malignancies xav tau txoj kev kho mob kom dav kom muaj feem ntau ntawm kev zam txim thiab kev kho tau zoo. Pab neeg txuas ntxiv txhim kho lawv txoj hauv kev thiab nthuav cov cim qhia kho mob rau CD7 CAR-T kev kho mob.

Xibfwb Lu txoj haujlwm tseem ceeb, uas twb tau kho ntau dua 300 tus neeg mob nrog CD7 CAR-T kev kho mob, sawv cev rau ib kauj ruam loj rau pem hauv ntej hauv kev kho mob T-cell malignancy. Txij no mus, pab neeg tau cog lus tias yuav sim tshuaj ntxiv thiab txhim kho cov txheej txheem kho mob CAR-T cell, kom ntseeg tau tias ntau tus neeg mob yuav tau txais txiaj ntsig los ntawm txoj hauv kev tshiab no.

Qhov kev sim theem I zoo no ntawm ASH 2024 qhia txog lub peev xwm ntawm CD7 CAR-T kev kho mob ua ib txoj kab tshiab hauv kev kho mob hematological oncology, muab kev cia siab rau cov neeg mob uas muaj cov mob uas kho tsis tau yav dhau los.